COCP15/1OVERVIEW OF ACTIVITY To bridge the gap between research and patient care, this CME activity will use the perspectives of clinical investigators on key management challenges and controversies in the treatment of PCa to assist medical oncologists, hematologists and hematology-oncology fellows, radiation oncologists, urologists, oncology nurses and other select healthcare practitioners in the formulation of up-to-date and appropriate treatment strategies. LEARNING OBJECTIVES
ACCREDITATION STATEMENT CME credit is no longer available for this issue CREDIT DESIGNATION STATEMENT CME credit is no longer available for this issue HOW TO USE THIS CME ACTIVITY CME credit is no longer available for this issue CONTENT VALIDATION AND DISCLOSURES FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Andrew J Armstrong, MD, ScM Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company; Consulting Agreements: Active Biotech AB, AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Ipsen, Sanofi; Contracted Research: Active Biotech AB, Astellas, Bristol-Myers Squibb Company, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Ipsen, Janssen Pharmaceuticals Inc, KangLaiTe USA, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Speakers Bureau: Amgen Inc, Dendreon Corporation, Pfizer Inc, Sanofi. Johann S de Bono, MBChB, MSc, PhD Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Sanofi; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Sanofi. Prof Ronald de Wit, MD, PhD Advisory Committee: Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreements: Astellas, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Roche Laboratories Inc, Sanofi; Contracted Research: Sanofi. Leonard G Gomella, MD Advisory Committee: Dendreon Corporation, GlaxoSmithKline; Consulting Agreements: Astellas, Bayer HealthCare Pharmaceuticals, Janssen Pharmaceuticals Inc; Contracted Research: Astellas, Dendreon Corporation, Janssen Pharmaceuticals Inc. Celestia S Higano, MD Advisory Committee: Abbott Laboratories, Astellas, Bayer HealthCare Pharmaceuticals, Genentech BioOncology, Millennium: The Takeda Oncology Company; Consulting Agreements: Abbott Laboratories, Astellas, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Genentech BioOncology, Medivation Inc, Millennium: The Takeda Oncology Company, Pfizer Inc; Contracted Research: Aragon Pharmaceuticals, AstraZeneca Pharmaceuticals LP, Dendreon Corporation, Genentech BioOncology, Medivation Inc, Millennium: The Takeda Oncology Company, Sanofi, Teva Pharmaceutical Industries Ltd; Co-ownership: CTI BioPharma. None of the products currently approved or in development at CTI BioPharma pertain to any form of treatment for prostate cancer. As such, Dr Higano’s involvement with CTI BioPharma does not pose any conflict of interest in her participation in this CME activity. Philip Kantoff, MD Advisory Committee: Astellas, Auven Therapeutics, Bellicum Pharmaceuticals Inc, BIND Therapeutics Inc, Blend Therapeutics, Endocyte/TRM Oncology, Medivation Inc, Metamark Genetics Inc, OncoCellMDx Inc, Progenics Pharmaceuticals Inc, Sanofi, SOTIO LLC, Tokai Pharmaceuticals; Consulting Agreements: Amgen Inc, Aragon Pharmaceuticals Inc, Archimedes Pharma US Inc, Bayer HealthCare Pharmaceuticals, BN ImmunoTherapeutics Inc, Celgene Corporation, Dendreon Corporation, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, GTx Inc, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, MorphoSys, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Teva Pharmaceutical Industries Ltd/OncoGenex Pharmaceuticals Inc. Eric A Klein, MD Clinical Trial Support: Medivation Inc; Consulting Agreements: Genomic Health Inc, Medivation Inc; Contracted Research: Genomic Health Inc. Daniel P Petrylak, MD Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, Millennium: The Takeda Oncology Company, Pfizer Inc, Sanofi; Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Sanofi; Grant Support: Dendreon Corporation, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Progenics Pharmaceuticals Inc. A Oliver Sartor, MD Advisory Committee: Bayer HealthCare Pharmaceuticals, Sanofi; Consulting Agreements: Algeta ASA, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Biscayne Pharmaceuticals Inc, Medivation Inc, OncoGenex Pharmaceuticals Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company, Progenics Pharmaceuticals Inc, Sanofi. Neal D Shore, MD Consulting Agreements: Abbott Laboratories, Astellas, Bayer HealthCare Pharmaceuticals, Ferring Pharmaceuticals, Genentech BioOncology, Genomic Health Inc, Millennium: The Takeda Oncology Company, Pfizer Inc, Sanofi. EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Teva Oncology and VisionGate Inc. RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose. This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors. This activity is supported by educational grants from Astellas/Medivation Inc, Bayer HealthCare Pharmaceuticals, Dendreon Corporation, Millennium: The Takeda Oncology Company and Sanofi. Hardware/Software Requirements: Last review date: January 2015 |